{Reference Type}: Journal Article
{Title}: New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome.
{Author}: Démoulins T;Techakriengkrai N;Ebensen T;Schulze K;Liniger M;Gerber M;Nedumpun T;McCullough KC;Guzmán CA;Suradhat S;Ruggli N;
{Journal}: Methods Mol Biol
{Volume}: 2786
{Issue}: 0
{Year}: 2024
暂无{DOI}: 10.1007/978-1-0716-3770-8_4
{Abstract}: While mRNA vaccines have shown their worth, they have the same failing as inactivated vaccines, namely they have limited half-life, are non-replicating, and therefore limited to the size of the vaccine payload for the amount of material translated. New advances averting these problems are combining replicon RNA (RepRNA) technology with nanotechnology. RepRNA are large self-replicating RNA molecules (typically 12-15 kb) derived from viral genomes defective in at least one essential structural protein gene. They provide sustained antigen production, effectively increasing vaccine antigen payloads over time, without the risk of producing infectious progeny. The major limitations with RepRNA are RNase-sensitivity and inefficient uptake by dendritic cells (DCs), which need to be overcome for efficacious RNA-based vaccine design. We employed biodegradable delivery vehicles to protect the RepRNA and promote DC delivery. Condensing RepRNA with polyethylenimine (PEI) and encapsulating RepRNA into novel Coatsome-replicon vehicles are two approaches that have proven effective for delivery to DCs and induction of immune responses in vivo.